Table 3.

Associations between physical performance and blood pressure change over time by baseline antihypertensive medication status^*.

	SBP	DBP	p-interaction
	β (95% CI)	β (95% CI)	Systolic BP	Diastolic BP
Grip strength
No HTN med use	0.77 (0.07, 1.45) †	0.43 (0.03, 0.83) †	0.78	0.62
Yes HTN med use	0.64 (−0.05, 1.32)	0.30(−0.09, 0.69)
Chair stand
No HTN med use	0.08 (−0.21; 0.38)	0.02 (−0.09, 0.13)	0.37	0.69
Yes HTN med use	0.25 (0.06, 0.43) †	−0.01 (−0.10, 0.08)
Gait speed
No HTN med use	0.96 (0.30, 1.62) ‡	0.50 (0.09, 0.90) †	0.51	0.80
Yes HTN med use	0.75 (−0.05, 1.35)	0.56 (0.15, 0.98) ‡

Notes: HTN, hypertension medication use; CI, confidence interval; DBP diastolic blood pressure; SBP, systolic blood pressure.

Bold print indicates Statistical significance

^†p≤0.05;

^‡p<0.01.

p-interaction represents the overall effect of the performance*antihypertensive medication use interaction in the model, by GEE.

Fully adjusted Model 3 was used to estimate all effect magnitude (β): age, race and ethnicity, clinic site, education, smoking status, alcohol use, cognitive function (Teng 3MS), self-rated health (SF12), time-varying physical activity (PASE score) and BMI (calculated using data from baseline, year 7 and 9 follow-up time points), prior fall, presence of at least one comorbidity (yes/no, osteoarthritis, COPD, kidney disease/failure, diabetes), and CVD.

^*Point estimates express the association between one standardized unit change in each performance measure and the associated BP change.